Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Summary
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Summary
The success of the Co-Dx PCR testing platform is contingent on receiving the necessary regulatory approvals from the U.S. FDA.The following is a summary of the Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript:
以下是co-diagnostics,Inc.(CODX)2024年第三季度业绩会成绩单摘要:
Business Progress:
业务进展:
Co-Diagnostics is currently seeking regulatory approval and marketing authorization for its forthcoming Co-Dx PCR testing platform.
Co-Diagnostics目前正在寻求其即将推出的Co-Dx PCR检测平台的监管批准和营销授权。
Opportunities:
机会：
The Co-Dx PCR testing platform represents a significant opportunity for market expansion and product innovation in the diagnostic testing market once regulatory approvals are obtained.
一旦获得监管批准，Co-Dx PCR检测平台将为市场扩张和产品创新提供重要机遇。
Risks:
风险：
The success of the Co-Dx PCR testing platform is contingent on receiving the necessary regulatory approvals from the U.S. FDA.
Co-Dx PCR检测平台的成功取决于从美国FDA获得必要的监管批准。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的详情，请参阅投资人关系网站。本文仅供投资者参考，不作任何指引或建议。
译文内容由第三方软件翻译。
